C Raby

470 total citations
16 papers, 359 citations indexed

About

C Raby is a scholar working on Molecular Biology, Cellular and Molecular Neuroscience and Organic Chemistry. According to data from OpenAlex, C Raby has authored 16 papers receiving a total of 359 indexed citations (citations by other indexed papers that have themselves been cited), including 8 papers in Molecular Biology, 5 papers in Cellular and Molecular Neuroscience and 3 papers in Organic Chemistry. Recurrent topics in C Raby's work include Receptor Mechanisms and Signaling (5 papers), Neuroscience and Neuropharmacology Research (3 papers) and Phosphodiesterase function and regulation (3 papers). C Raby is often cited by papers focused on Receptor Mechanisms and Signaling (5 papers), Neuroscience and Neuropharmacology Research (3 papers) and Phosphodiesterase function and regulation (3 papers). C Raby collaborates with scholars based in United States and Switzerland. C Raby's co-authors include Mark R. Emmerling, M. Desiree Watson, Katharyn Spiegel, Alex E. Roher, Maria Cristina Morganti-Kossmann, Yu‐Min Kuo, Philip F. Stahel, Lori M. Evans, Thomas Kossmann and Michael J. Callahan and has published in prestigious journals such as Annals of the New York Academy of Sciences, Journal of Neurochemistry and Journal of Pharmacology and Experimental Therapeutics.

In The Last Decade

C Raby

15 papers receiving 342 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
C Raby United States	8	170	141	108	74	72	16	359
R Kalaria United States	9	164 1.0×	319 2.3×	83 0.8×	145 2.0×	67 0.9×	14	445
M. Desiree Watson United States	9	221 1.3×	410 2.9×	137 1.3×	133 1.8×	85 1.2×	10	614
Bolati Kuerban Japan	11	177 1.0×	183 1.3×	46 0.4×	69 0.9×	70 1.0×	17	405
Arthur Kay United States	10	106 0.6×	192 1.4×	66 0.6×	54 0.7×	52 0.7×	17	433
Eileen McCracken United Kingdom	7	180 1.1×	72 0.5×	132 1.2×	144 1.9×	105 1.5×	8	426
Yea Seul Shin Australia	6	158 0.9×	112 0.8×	154 1.4×	72 1.0×	59 0.8×	6	384
A. Tallón-Barranco Spain	14	156 0.9×	191 1.4×	174 1.6×	56 0.8×	106 1.5×	18	541
Ya-Ni Huang Taiwan	10	175 1.0×	32 0.2×	137 1.3×	87 1.2×	71 1.0×	10	428
Nazaret Gamez United States	8	166 1.0×	187 1.3×	45 0.4×	75 1.0×	70 1.0×	14	417
Laura E. Palmer United Kingdom	7	180 1.1×	382 2.7×	114 1.1×	123 1.7×	102 1.4×	8	648

Countries citing papers authored by C Raby

Since Specialization

Citations

This map shows the geographic impact of C Raby's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by C Raby with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites C Raby more than expected).

Fields of papers citing papers by C Raby

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by C Raby. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by C Raby. The network helps show where C Raby may publish in the future.

Co-authorship network of co-authors of C Raby

This figure shows the co-authorship network connecting the top 25 collaborators of C Raby. A scholar is included among the top collaborators of C Raby based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with C Raby. C Raby is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

16 of 16 papers shown

Emmerling, Mark R., M. Desiree Watson, C Raby, & Katharyn Spiegel. (2000). The role of complement in Alzheimer’s disease pathology. Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease. 1502(1). 158–171. 86 indexed citations

Tecle, Haile, Roy D. Schwarz, Stephen D. Barrett, et al.. (2000). CI-1017, a functionally M1-selective muscarinic agonist: design, synthesis, and preclinical pharmacology. Pharmaceutica Acta Helvetiae. 74(2-3). 141–148. 11 indexed citations

Emmerling, Mark R., Maria Cristina Morganti-Kossmann, Thomas Kossmann, et al.. (2000). Traumatic Brain Injury Elevates the Alzheimer's Amyloid Peptide Aβ₄₂ in Human CSF: A Possible Role for Nerve Cell Injury. Annals of the New York Academy of Sciences. 903(1). 118–122. 80 indexed citations

Schwarz, Roy D., Michael J. Callahan, Linda L. Coughenour, et al.. (1999). Milameline (CI-979/RU35926): A Muscarinic Receptor Agonist with Cognition-Activating Properties: Biochemical and In Vivo Characterization. Journal of Pharmacology and Experimental Therapeutics. 291(2). 812–822. 33 indexed citations

Raby, C, Maria Cristina Morganti-Kossmann, Thomas Kossmann, et al.. (1998). Traumatic Brain Injury Increases β‐Amyloid Peptide 1‐42 in Cerebrospinal Fluid. Journal of Neurochemistry. 71(6). 2505–2509. 90 indexed citations

Spiegel, K., C Raby, William J. Lipinski, et al.. (1998). Activation of the classical complement pathway by NMDA injection into the striatum of the neonatal rat. Molecular Immunology. 35(6-7). 404–404. 1 indexed citations

Raby, C, et al.. (1996). [USE OF TRYPSIN FOR THE SIMULTANEOUS AND SPECIFIC DETERMINATION FACTORS DEPLETED BY ANTI-VITAMIN K AGENTS. (THE "K-TEST")].. PubMed. 3. 253–69.

Jaén, Juan C., Stephen D. Barrett, Mark R. Brann, et al.. (1995). In vitro and in vivo evaluation of the subtype-selective muscarinic agonist PD 151832. Life Sciences. 56(11-12). 845–852. 18 indexed citations

Emmerling, Mark R., V. Gregor, Michael J. Callahan, et al.. (1995). CI‐1002: A Combined Acetylcholinesterase Inhibitor and Muscarinic Antagonist ¹. CNS Drug Reviews. 1(1). 27–49. 2 indexed citations

10.

Tecle, Haile, Robert E. Davis, Tara Mirzadegan, et al.. (1995). (±)-1-Azabicyclo[2.2.1]heptan-3-one, O-(3-methyl-5-aryl-2-penten-4-ynyl) oximes: Potent muscarinic agonists. Bioorganic & Medicinal Chemistry Letters. 5(6). 637–642. 4 indexed citations

11.

Emmerling, Mark R., V. Gregor, Roy D. Schwarz, et al.. (1994). PD 142676 (CI 1002), a novel anticholinesterase and muscarinic antagonist. Molecular Neurobiology. 9(1-3). 93–106. 9 indexed citations

12.

Davis, Robert E., C Raby, Michael J. Callahan, et al.. (1993). Chapter 54: Subtype selective muscarinic agonists: potential therapeutic agents for Alzheimer's disease. Progress in brain research. 98. 439–445. 19 indexed citations

13.

Delage, Christiane, et al.. (1988). Structure du (nitro-3 pyridyl-2)thio-3 1H-triazole-1,2,4. Acta Crystallographica Section C Crystal Structure Communications. 44(12). 2187–2189. 1 indexed citations

14.

Raby, C, et al.. (1965). [A new synthetic hemostatic and antihemorrhagic].. PubMed. 23. 1241–6. 1 indexed citations

15.

Raby, C, et al.. (1965). [New synthetic antihemorrhagic and hemostatic].. PubMed. 5(4). 389–403. 2 indexed citations

16.

Raby, C & M Servelle. (1962). [Exact determination of the actual blood heparin content at the moment when it is neutralized by polybrene or protamine sulfate].. PubMed. 2. 325–8. 2 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact